Sheba has a long history with Africa, and for many years now, we have been proud to provide aid, share knowledge, and empower medical professionals across this great continent. Recently, we were delighted to partner with the International Society of Ocular Oncology...
Aug 24, 2023 | Latest News
In 2019, Sheba made medical history and launched the ARC Innovation Center. ARC, which stands for Accelerate, Redesign, and Collaborate, was designed to "improve patient care, using innovation to provide real value to patients," explains Prof. Eyal Zimlichman, ARC...
Jul 28, 2023 | Latest News
The highly-anticipated REACT 2023 online conference took place on July 27th, with more than 250 attendees from around the world. Physicians and medical students from over 25 countries met to gain valuable insights into the latest developments in cancer care from...
The latest milestone in Sheba’s efforts to advance healthcare through international collaboration, we are pleased to announce a new partnership with PureHealth, the largest integrated healthcare system in the Middle East.
Sheba Medical Center and Vietnam’s Vin University Join Forces Under a New Memorandum of Understanding
Sheba has recently signed a landmark memorandum of understanding (MOU) with Vin University in Vietnam, which will set the stage for exciting knowledge-sharing and medical training collaborations.
A Global Gamechanger: Sheba and the NIH Join Forces to Develop a Revolutionary Pan-Coronavirus Vaccine
Sheba Pandemic Research Institute (SPRI) has joined a groundbreaking collaboration with the National Institutes of Health (NIH)’s Vaccine Research Center, the Walter Reed Army Institute of Research, and pharmaceutical giant Sanofi. Researchers aim to develop booster vaccines that can provide comprehensive protection against multiple coronavirus variants, including SARS-CoV-2, revolutionizing virus care worldwide. Sheba’s COVID-19 research program, which involves over 9,000 healthcare workers, will serve as the framework for the design of the pan-coronavirus vaccine.